These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10528328)

  • 21. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.
    Entacapone to Tolcapone Switch Study Investigators
    Mov Disord; 2007 Jan; 22(1):14-9. PubMed ID: 17089403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolcapone: a review of its use in the management of Parkinson's disease.
    Keating GM; Lyseng-Williamson KA
    CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
    Onofrj M; Thomas A; Iacono D; Di Iorio A; Bonanni L
    Eur Neurol; 2001; 46(1):11-6. PubMed ID: 11455177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Modern therapeutic possibilities in Parkinson disease].
    Ludin HP
    Schweiz Med Wochenschr; 1999 May; 129(19):741-7. PubMed ID: 10407949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
    Marsala SZ; Gioulis M; Ceravolo R; Tinazzi M
    Clin Neuropharmacol; 2012; 35(4):185-90. PubMed ID: 22805229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment in Parkinson disease].
    Takáts A
    Orv Hetil; 2004 Apr; 145(15):833-4. PubMed ID: 15188639
    [No Abstract]   [Full Text] [Related]  

  • 27. Current advances in Parkinson's disease.
    Ball J
    Trends Neurosci; 2001 Jul; 24(7):367-9. PubMed ID: 11467283
    [No Abstract]   [Full Text] [Related]  

  • 28. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
    Goetz CG; Poewe W; Rascol O; Sampaio C
    Mov Disord; 2005 May; 20(5):523-39. PubMed ID: 15818599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].
    Krivonos OV; Fedorova NV; Chigir' IP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(1):24-30. PubMed ID: 14870689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of tolcapone in the treatment of Parkinson's disease.
    Leegwater-Kim J; Waters C
    Expert Rev Neurother; 2007 Dec; 7(12):1649-57. PubMed ID: 18052761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
    Nyholm D; Johansson A; Lennernäs H; Askmark H
    Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of entacapone in the management of Parkinson's disease.
    Brooks DJ; Forsyth D; Playfer JR; Williams AC
    Hosp Med; 2000 Apr; 61(4):267-71. PubMed ID: 10858804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
    Fahn S
    Neurology; 1998 May; 50(5 Suppl 5):S1-2. PubMed ID: 9591515
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of Parkinson's disease with COMT inhibitors: tolcapone].
    Avila A; Kulisevsky J
    Neurologia; 1998; 13 Suppl 1():66-71. PubMed ID: 9859687
    [No Abstract]   [Full Text] [Related]  

  • 39. [Tolcapone treatment of late stages of Parkinson's disease].
    Fedorova NV; Chigir' IP; Krivonos OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(6):31-4. PubMed ID: 15984185
    [No Abstract]   [Full Text] [Related]  

  • 40. [COMT inhibition with tolcapone].
    Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.